ORIONS Money Stocks

[novicetrader]

FCSC...on alert watch,expecting news soon.Been 4 weeks from end-Feb.
From 3/9 pr:


In February 2017, the first patient was dosed in the Phase I portion of the Phase I/II clinical trial of FCX-007 for the treatment of RDEB. The primary objective of this open-label clinical trial is to evaluate the safety of FCX-007 in RDEB patients. Additionally, the trial will assess the mechanism of action of FCX-007 through the evaluation of type VII collagen expression and the presence of anchoring fibrils, as well as the efficacy of FCX-007 through evidence of wound healing. Six adult patients are targeted for the Phase I portion of the trial.

Additional patients are expected to be dosed with FCX-007 after a required four-week waiting period and subsequent health assessment of the first patient. Twelve-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in the Phase I portion of this trial are expected in the third quarter of 2017.